Skip to content

Evaluation of the skin window technique in patients with complex regional pain syndrome

Evaluation of the skin window technique in patients with complex regional pain syndrome - Skin window technique in CRPS

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON32121
Enrollment
60
Registered
2008-03-18
Start date
2008-07-04
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complex Regional Pain Syndrome Posttraumatic Dystrophy Reflex Sympathic Dystrophy

Interventions

None listed

Sponsors

Leids Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: * Patients should fulfill the criteria for CRPS I according to the clinical diagnostic criteria of the IASP: o Continuing pain, allodynia or hyperalgesia that is not limited to the territory of a single peripheral nerve and is disproportionate to the inciting event. o Evidence at some time of edema, changes in skin blood flow or abnormal sudomotoric activity in the region of the pain o This diagnosis is excluded by the existence of conditions that would otherwise account for the degree of pain and dysfunction. ;* Patients should fulfill the diagnostic criteria for CRPS I according to Veldman: o Four or five of: * Unexplained diffuse pain * Difference in skin color relative to the other limb * Diffuse edema * Difference in skin temperature relative to the other limb * Limited active range of motion o Occurrence or increase of the above signs and symptoms after use o The above signs and symptoms are present in an area larger than the area of primary injury or operation and include the area distal to the primary injury. ;* Patients should have one affected and one unaffected arm.

Exclusion criteria

Exclusion criteria: * Patients and controls should have no history of any (other) chronic inflammatory diseases. * Patients and controls are excluded when immunosuppressive medication is used. * Patients and controls are excluded when having an infectious disease at the time of the measurements.

Design outcomes

Primary

MeasureTime frame
Primary outcome are the differences between patients and controls with respect to cytokine profiles, de availability and amount of myeloperoxidase and the total amount of Gc-globulin and 1,25(OH)2vitaminD3.

Secondary

MeasureTime frame
Secondary outcome is the difference within patients when comparing between the affected and the unaffected arm. Another secondary outcome is the difference within control subjects when comparing between both arms.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)